Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART)

The main purpose of this study is to understand how patients with giant cell arteritis (GCA) respond to an investigational drug called abatacept (also called Orencia). Abatacept is being tested to determine if it is effective in treating GCA. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA) for treating GCA. We will use your personal health information, information from the tests and procedures done for the study, and information about how the study drug affects you to help determine if the study drug abatacept is safe and effective in treating GCA.

Study Duration: Up to 18 months

Disease(s): Giant Cell Arteritis (GCA)